このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Long-term Follow-up of Actifit® Meniscal Scaffold Patients.

2026年8月31日 更新者:Orteq Sports Medicine

This study will collect retrospective patient data of Actifit patients (medial and lateral, isolated cases as well as cases with concomitant procedures), including pre-op and any post-op imaging, for 120 retrospective Actifit patients, to account for drop-outs and patients refusing a follow-up visit/follow-up imaging.

Each patient without evidence of previous removal of the scaffold, revision to arthroplasty or joint-modifying surgery at the index knee will be contacted by the site, first by phone, to check whether the Actifit device is still in place or not. If no longer in place, patient's situation will be clearly documented, this will preferentially be done via phone or, if necessary, via a prospective visit. If the Actifit is still in place, a prospective follow-up visit will be organised so that patient's current situation can be documented. The prospective follow-up visit may be via an in-person clinic visit (preferred since the visit, provided the patients agrees, includes imaging), telephone or video conference. Any newly occurring events during this prospective visit will also be documented. Of the 120 retrospective patients, we anticipate a group of about 60-100 study participants with the Actifit still in place and being invited to a prospective follow-up visit.

Consent will be requested to collect specific questionnaires (IKDC, KOOS, VAS-pain and, in case available at baseline, Lysholm) and, in case the study participant also agrees to this, an X-Ray/MRI will be collected, provided any previous imaging is > 365 days old.

調査の概要

状態

まだ募集していません

詳細な説明

This multicentre study is intended to document the mid- and long-term clinical safety and effectiveness in patients treated with the Actifit meniscus scaffold.

The purpose of this study is to document the mid- and long-term safety and effectiveness of the Actifit Meniscal Scaffold and allow comparisons with other treatment modalities.

Primary Objective:

The primary objective of this study is to collect data to document the safety and effectiveness (IKDC) of the Actifit Meniscal Scaffold at 4-6 years in study participants with an Actifit procedure for the medial or lateral meniscus (isolated or in combination with one or more additional procedures).

Secondary Objectives: The secondary objectives of this study are: 1. To collect safety and effectiveness (IKDC) data on the Actifit Meniscal Scaffold in medial, lateral, isolated or combined procedures at 7-12 years and 12+ years and compare to baseline.2. To collect safety and effectiveness (IKDC) data on the Actifit Meniscal Scaffold in isolated procedures of the medial or lateral meniscus, as well as in pooled isolated and combined procedures at the medial or lateral meniscus at 4-6 years, 7-12 years and 12+ years and compare to baseline.

Additional objectives: 1. To compare VAS, KOOS and, if available, Lysholm preop - to mid- and long-term postoperative outcomes for patients treated with the Actifit® scaffold. 2. To compare preop- (if available) to mid- and long-term postoperative radiographs (baseline to 4-6 years and to the last available radiographs) for patients treated with the Actifit® scaffold. 3. To assess the knee on MRI at mid- and long-term follow-up intervals, if available, and, compare to baseline MRI. 4. To assess (serious) events related to the Actifit device and/or procedure through each of the time points: 4-6 years (this includes any clinically relevant event since the Actifit® operation), 7-12 years and 12+ years.

Two co-primary endpoints in Actifit® procedures at the medial or lateral meniscus (isolated or combined) at 4-6 years of follow-up: 1. Efficacy: the percent improvement in the IKDC from baseline to the 4-6 years follow-up point. 2. Safety/survival: the percentage of study participants at 4-6 years of follow-up, with the device (Actifit®) still in place (not removed); and who did not require conversion to arthroplasty or other joint-modifying surgery (e.g. osteotomy) (Kaplan-Meier survival curves).

Descriptive statistics will be presented for the secondary and additional endpoints below.

Secondary endpoints: Efficacy: Long-term efficacy: IKDC improvement from baseline to 7 - 12 years and 12+ years follow-up in Actifit® procedures (medial or lateral, isolated or combined). Mid- and long-term efficacy: IKDC improvement from baseline to 4-6 years, 7 - 12 years and 12+ years follow-up in Actifit Meniscal Scaffold procedures in isolated procedures of the medial or lateral meniscus, as well as in pooled isolated and combined procedures at the medial or lateral meniscus Safety: Long-term safety/survival (device in place, no joint-modifying surgery) at 7 - 12 years and 12+ years follow-up) in Actifit procedures (medial or lateral, isolated or combined) (Kaplan-Meier survival curves). Mid- and long-term safety/survival (device in place, no joint-modifying surgery) at 4-6 years, 7 - 12 years and 12+ years follow-up of Actifit Meniscal Scaffold procedures in isolated procedures of the medial or lateral meniscus, as well as in pooled isolated and combined procedures at the medial or lateral meniscus, (Kaplan-Meier survival curves).

Additional Endpoints:

Efficacy: Compare preop- to mid- and long-term (4-6, 7-12 years and 12+ years) postoperative outcomes (VAS, KOOS, and, if available, Lysholm) for patients treated with the Actifit scaffold. Compare preop- to mid- and long-term postoperative radiographs for patients treated with the Actifit scaffold (joint space height, Kellgren-Lawrence score, …) at 4-6 years and the last available radiographs (that are > 365 days passed the 4-6 year images). Assess the knee on MRI at long-term follow-up visits: 4-6 and the last available MRI (that is > 365 days passed the 4-6 year MRI), including the WORMS score and other relevant assessments to baseline MRI (contrast or no contrast, before or ≤ 6 months post Actifit procedure) when available. If baseline MRI is not available: assess knee and meniscal condition at long-term follow-up time points.

Safety: Procedure related (serious) events and (serious) device related incidents, side-effects through each of the time points: 4-6 years and since the Actifit operation, 7-12 years and 12+ years.

All endpoints will be analysed separately for adherence to instructions for use, isolated medial or lateral procedures, pooled (isolated and combined) medial or lateral procedures, as well as pooled analyses for the overall cohort (medial, lateral, isolated, combined). Except for the analyses of the overall cohort, the analyses will be exploratory only and will not be used to make claims.

研究の種類

観察的

入学 (推定)

120

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Lieven Huysse, MD
  • 電話番号:+32 477 96 06 23
  • メール:lhuysse@orteq.com

研究連絡先のバックアップ

研究場所

    • Oost-Vlaanderen
      • Ghent、Oost-Vlaanderen、ベルギー、9000
        • University Hospital Gent
        • コンタクト:
          • Nele Arnout, MD
          • 電話番号:+329332 22 51
          • メール:bws@uzgent.be

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

Patients implanted with an Actifit scaffold more than 4 years ago with the implant still intact and a baseline IKDC score.

説明

Inclusion:

At time of operation, with respect to the involved knee:

  • Patients with irreparable, painful and/or dysfunctional meniscal tissue loss having undergone partial meniscectomy.
  • Sufficient rim over the entire circumference of the meniscus to ensure stable fixation.
  • Well aligned knee joint (varus/valgus <5o) or willing to correct alignment at implant surgery
  • Stable knee joint or ACL deficiencies corrected within 12 weeks after implantation of Actifit.
  • ICRS classification ≤ 3.
  • No more than 3 prior meniscal surgeries on the involved knee.

    • Skeletally mature men or women, aged 16 to 50 years at time of Actifit procedure.
    • Actifit implantation at a minimum of 4 years ago
    • Willing to participate in this long-term follow-up study.

Exclusion:

At time of operation:

  • PCL insufficiency of the involved knee.
  • Significant uncorrected malformations, axial malalignment in the ipsilateral leg.
  • Documented allergy to any of the product components.
  • Systemic or local infection at the time of the operation.
  • Overweight at the time of operation (defined as BMI greater than 35kg/m²)
  • Systemic administration of any type of corticosteroid, antineoplastics, immune-stimulating or immunosuppressive agent within 30 days before or after implantation of Actifit.
  • Evidence of osteonecrosis in the involved knee at the time of the operation.
  • Medical history at time of operation that is positive, for, but not restricted to, the following diseases:

Rheumatoid arthritis Relapsing polychondritis Severe degenerative osteoarthrosis Inflammatory arthritis

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
Patients who have been treated with an Actifit meniscal scaffold
For patients implanted with an Actifit device 4 - 12+ years ago and still have the device in place, consent will be requested to collect specific questionnaires (IKDC, KOOS, VAS-pain) and, in case the study participant also agrees to this, an X-Ray/MRI will be collected, provided any previous imaging is > 365 days old.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Efficacy of the Actifit Meniscal Scaffold
時間枠:4-6 years
The primary objective of this study is to collect data to document the effectiveness (IKDC) of the Actifit Meniscal Scaffold at 4-6 years in study participants with an isolated Actifit procedure for the medial meniscus Description: Effectiveness: For the IKDC. 0 is the worst score and indicates extreme pain and functional limitation. 100 is the best score and indicates no pain and no functional limitation.
4-6 years
Safety of the Actifit Meniscal Scaffold
時間枠:4-6 years
Safety/survival: the percentage of study participants at 4-6 years of follow-up, with the device (Actifit) still in place (not removed); and who did not require conversion to arthroplasty or other joint-modifying surgery (e.g. osteotomy) (Kaplan-Meier survival curves) will be calculated.
4-6 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディチェア:Clayton Wilson、Orteq Sports Medicine

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月1日

一次修了 (推定)

2028年9月1日

研究の完了 (推定)

2028年9月1日

試験登録日

最初に提出

2026年7月28日

QC基準を満たした最初の提出物

2026年8月31日

最初の投稿 (実際)

2026年9月2日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月2日

QC基準を満たした最後の更新が送信されました

2026年8月31日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

試験データ・資料

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する